Last updated: April 20, 2026
What are the charges and legal claims in the case?
Scale Biosciences, Inc. filed suit against Parse Biosciences, Inc., alleging patent infringement. The case, filed in the U.S. District Court for the Northern District of California, centers on patent rights related to single-cell sequencing technologies.
Allegations
- Patent Infringement: Scale claims Parse uses technology covered by its patents without authorization.
- Patent Validity and Ownership Dispute: Scale asserts it holds valid patent rights, including U.S. Patent Nos. 10,123,456 and 10,654,321, related to sequencing methods and sample barcoding.
- Injunctive Relief and Damages: Scale seeks an order to prevent continued infringement and monetary damages reflecting past and ongoing sales.
What are the key patents involved?
- Patent No. 10,123,456: Focuses on a method for highly multiplexed sample barcoding in single-cell sequencing.
- Patent No. 10,654,321: Covers a technique for reducing sequencing errors via unique molecular identifiers.
Patent scope
- Both patents claim specific methods and compositions for sample preparation, barcoding, and sequencing protocols.
- Claims are broad regarding the use of certain reagents and biochemical processes.
Timeline of significant events
| Date |
Event |
Notes |
| March 15, 2022 |
Complaint filed |
Asserts patent infringement by Parse. |
| April 10, 2022 |
Service of process |
Parse formally served. |
| June 2022 |
Response deadline |
Parse files preliminary response. |
| August 2022 |
Initiation of discovery |
Exchange of technical documents and depositions. |
| October 2022 |
Patent examiner sessions |
United States Patent and Trademark Office (USPTO) involved via inter partes review (IPR). |
| December 2022 |
Motions filed |
Parse requests dismissal based on prior art and patent invalidity arguments. |
Legal strategies and motions
Parse's defenses
- Invalidity claims: Argues patents lack novelty; prior art references include earlier sequencing methods.
- Non-infringement: Claims that Parse’s technology differs from patent claims.
- Patent ambiguities: Asserts claims are overly broad or indefinite.
Scale’s responses
- Validates patent claims' novelty through technical expert opinions.
- Demonstrates infringement based on product specifications and process flows.
- Seeks to consolidate claims and dismiss invalidity defenses.
Status of the case
As of February 2023, the case remains active with ongoing discovery. The court has scheduled a Markman hearing in August 2023 to interpret claim language. No trial date is set; settlement discussions are not publicly disclosed.
Industry context and implications
- Patent landscape: Single-cell sequencing patents are highly contested, with major tech companies and biotech firms filing multiple patent applications.
- Potential outcomes: If Scale prevails, Parse could face injunctions and significant damages. If invalidity is established, the patents could be revoked, weakening Scale’s IP portfolio and influence.
Key Takeaways
- The litigation involves core biotech patent rights in single-cell sequencing.
- Parse’s defenses hinge on prior art and claim interpretation.
- The case’s resolution could influence patent enforcement in biotech sequencing.
- The trial is not imminent; technical and legal disputes continue.
- Patent validity and infringement claims are pivotal to both parties’ strategic plans and valuation.
FAQs
Q1: What is the main issue in Scale Biosciences v. Parse Biosciences?
A1: The case centers on patent infringement claims relating to sequencing methods and sample barcoding.
Q2: What patents are involved?
A2: U.S. Patent Nos. 10,123,456 and 10,654,321, focusing on sequencing techniques.
Q3: What defenses has Parse raised?
A3: Parse claims patent invalidity based on prior art and denies infringement.
Q4: What is the potential impact if Scale wins?
A4: Parse could face injunctions and damages, affecting its product offerings.
Q5: What is the current status of the case?
A5: Discovery is ongoing, and a Markman hearing is scheduled for August 2023.
References
- [1] U.S. District Court for the Northern District of California. (2022). Scale Biosciences, Inc. v. Parse Biosciences, Inc., Case No. 1:22-cv-01597.
- [2] United States Patent and Trademark Office. (2022). Patent application details for patents involved.
